Literature DB >> 15904704

Progestin-facilitated lordosis of hamsters may involve dopamine-like type 1 receptors in the ventral tegmental area.

Kanako Sumida1, Alicia A Walf, Cheryl A Frye.   

Abstract

Hamsters are highly-dependent upon the central actions of progesterone (P) to facilitate sexual behavior. P has membrane mechanisms of action in the ventral tegmental area (VTA) to facilitate sexual receptivity of rodents. The present experiments examined whether P's membrane actions in the VTA include dopamine (DA) type 1 (D(1)) or dopamine type 2 (D(2)) receptors. Ovariectomized (ovx), estradiol (E(2))- and P-primed hamsters were infused with D(1) (Experiment 1) or D(2) (Experiment 2) antagonists or agonists (0 or 100 ng) to the VTA and tested 30 min later. The D(1) agonist, SKF38393, enhanced P-facilitated lordosis. The D(1) antagonist, SCH23390, attenuated P-facilitated lordosis. The D(2) agonist, quinpirole and the D(2) antagonist, sulpiride, had no significant effects on P-facilitated lordosis. These data suggest that, in hamsters, P's actions for lordosis may involve D(1) receptors in the VTA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15904704     DOI: 10.1016/j.bbr.2005.02.013

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  14 in total

Review 1.  Pregnane xenobiotic receptors and membrane progestin receptors: role in neurosteroid-mediated motivated behaviours.

Authors:  C A Frye; C J Koonce; A A Walf
Journal:  J Neuroendocrinol       Date:  2013-11       Impact factor: 3.627

2.  Engaging in paced mating, but neither exploratory, anti-anxiety, nor social behavior, increases 5alpha-reduced progestin concentrations in midbrain, hippocampus, striatum, and cortex.

Authors:  Cheryl A Frye; Jason J Paris; Madeline E Rhodes
Journal:  Reproduction       Date:  2007-03       Impact factor: 3.906

Review 3.  Novel substrates for, and sources of, progestogens for reproduction.

Authors:  Cheryl Anne Frye
Journal:  J Neuroendocrinol       Date:  2011-11       Impact factor: 3.627

Review 4.  Membrane actions of progestins at dopamine type 1-like and GABAA receptors involve downstream signal transduction pathways.

Authors:  Cheryl A Frye; Alicia A Walf
Journal:  Steroids       Date:  2008-02-08       Impact factor: 2.668

5.  Activity of protein kinase C is important for 3alpha,5alpha-THP's actions at dopamine type 1-like and/or GABAA receptors in the ventral tegmental area for lordosis of rats.

Authors:  Cheryl A Frye; Alicia A Walf
Journal:  Brain Res Bull       Date:  2008-07-31       Impact factor: 4.077

6.  Infusions of anti-sense oligonucleotides for DARPP-32 to the ventral tegmental area reduce effects of progesterone- and a dopamine type 1-like receptor agonist to facilitate lordosis.

Authors:  Cheryl A Frye; Alicia A Walf
Journal:  Behav Brain Res       Date:  2009-09-24       Impact factor: 3.332

7.  Progesterone reduces hyperactivity of female and male dopamine transporter knockout mice.

Authors:  Cheryl A Frye; Ichiro Sora
Journal:  Behav Brain Res       Date:  2010-01-20       Impact factor: 3.332

8.  In the ventral tegmental area, G-proteins mediate progesterone's actions at dopamine type 1 receptors for lordosis of rats and hamsters.

Authors:  Sandra M Petralia; Cheryl A Frye
Journal:  Psychopharmacology (Berl)       Date:  2006-02-16       Impact factor: 4.530

9.  Infusions of 3alpha,5alpha-THP to the VTA enhance exploratory, anti-anxiety, social, and sexual behavior and increase levels of 3alpha,5alpha-THP in midbrain, hippocampus, diencephalon, and cortex of female rats.

Authors:  Cheryl A Frye; Madeline E Rhodes
Journal:  Behav Brain Res       Date:  2007-08-31       Impact factor: 3.332

10.  Exploratory, anti-anxiety, social, and sexual behaviors of rats in behavioral estrus is attenuated with inhibition of 3alpha,5alpha-THP formation in the midbrain ventral tegmental area.

Authors:  Cheryl A Frye; Jason J Paris; Madeline E Rhodes
Journal:  Behav Brain Res       Date:  2008-06-11       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.